Edition:
United States

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

6.56CAD
17 Nov 2017
Change (% chg)

$-0.19 (-2.81%)
Prev Close
$6.75
Open
$6.78
Day's High
$6.78
Day's Low
$6.51
Volume
43,216
Avg. Vol
58,413
52-wk High
$14.17
52-wk Low
$2.75

Latest Key Developments (Source: Significant Developments)

Aurinia reports Q3 loss per share $0.16
Tuesday, 14 Nov 2017 04:00pm EST 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020.  Full Article

Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​
Monday, 23 Oct 2017 05:43pm EDT 

Oct 23 (Reuters) - Aurinia Pharmaceuticals Inc : :Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​.Robert Duggan had previously reported 7.2 percent stake in Aurinia Pharmaceuticals Inc as on April 21, 2017.  Full Article

Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise
Friday, 20 Oct 2017 08:00am EDT 

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​.Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES.Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​.  Full Article

Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​
Thursday, 10 Aug 2017 04:30pm EDT 

Aug 10 (Reuters) - Aurinia Pharmaceuticals Inc -:Aurinia reports second quarter 2017 financial results, and provides operational highlights.Aurinia Pharmaceuticals Inc qtrly loss per share $‍0.03​.Aurinia Pharmaceuticals - ‍believe, based on current plans, co has financial resources to complete aurora trial and regulatory submission process​.  Full Article

Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis
Wednesday, 17 May 2017 04:02pm EDT 

May 17 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis.Aurinia Pharmaceuticals - Trial to recruit 320 patients, intended to support full marketing approval of voclosporin for patients with LN.  Full Article

Aurinia announces development plans for Voclosporin in Europe and Japan
Thursday, 6 Apr 2017 05:12pm EDT 

Aurinia Pharmaceuticals Inc : Aurinia announces development plans for Voclosporin in Europe and Japan . Aurinia Pharmaceuticals Inc - on track to initiating global Aurora study this quarter .Aurinia-Confirmatory data that can be generated from aurora trial, aura-lv phase iib study should support regulatory submissions in US, Europe, Japan.  Full Article

Aurinia says public offering of 22.3 mln shares priced at $6.75 per share
Tuesday, 14 Mar 2017 08:00am EDT 

Aurinia Pharmaceuticals Inc : Aurinia prices us$150.5 million public offering of common shares . Aurinia pharmaceuticals inc says pricing of its underwritten public offering of 22.3 million common shares .Aurinia pharmaceuticals inc says shares are being sold at a public offering price of us$6.75 per share.  Full Article

Aurinia announces public offering of common shares
Monday, 13 Mar 2017 04:01pm EDT 

Aurinia Pharmaceuticals Inc : Aurinia announces public offering of common shares .Aurinia Pharmaceuticals-to use net proceeds of offering for research, development activities, phase 3 clinical trial activities for lupus nephritis.  Full Article

Aurinia Q4 loss per share $0.21
Thursday, 9 Mar 2017 08:30am EST 

Aurinia Pharmaceuticals Inc : Aurinia reports fourth quarter and full year 2016 financial results and recent operational highlights .Q4 loss per share $0.21.  Full Article

Aurinia Pharmaceuticals announces Voclosporin results from Japanese Phase I study
Tuesday, 14 Feb 2017 07:00am EST 

Aurinia Pharmaceuticals Inc : Aurinia Pharmaceuticals Inc announces results from Japanese Phase I ethnic bridging study for Voclosporin . Aurinia Pharmaceuticals Inc - data support continued development of Voclosporin in Japanese patient population . Aurinia Pharmaceuticals Inc - there were no unusual or unexpected safety signals in study. . Aurinia - PK parameters in Japanese patients were generally consistent with previously evaluated PK parameters in non-Japanese volunteers .Aurinia Pharmaceuticals Inc says to share findings of study with Japanese pharmaceuticals, medical devices agency in Q2,.  Full Article

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights